Interline raises $92M for drug discovery of dysfunctional proteins

By The Science Advisory Board staff writers

May 14, 2021 -- Interline Therapeutics has raised $92 million to be used to expand its research platform and advance six preclinical therapeutic programs.

Foresite Capital and ARCH Venture Partners co-led the financing, which will be used to support platform development and therapeutic programs focused on inflammatory disease and cancer. Interline will use a combination of genomics, proteomics, structural biology, and computational chemistry to systematically map and modulate proteins to develop a precision medicine platform capable of correcting dysfunctional disease networks.

The company will continue to collaborate with Foresite Labs in the fields of data science and genomics. Interline also launched with foundational collaborations with University of California, San Francisco and Memorial Sloan Kettering Cancer Center, as well as an internationally recognized team of founding scientific advisors.

Copyright © 2021

CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter